Aug. 24 at 11:51 PM
$EBS yup, x15 (140$ per share) from here to average among Biotechs based on price/sales ratio:
"In spite of the firm bounce in price, Emergent BioSolutions may still be sending very bullish signals at the moment with its price-to-sales (or "P/S") ratio of 0.6x, since almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 9.1x and even P/S higher than 63x are not unusual."
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-ebs/emergent-biosolutions/news/improved-revenues-required-before-emergent-biosolutions-inc